-
Tobramycin
- indication:For the treatment of pseudomonas aeruginosa lung infections. Also being investigated for use in the treatment of sinus infections.
- pharmacologypharmacology:
- mechanism: Tobramycin binds irreversibly to one of two aminoglycoside binding sites on the 30 S ribosomal subunit, inhibiting bacterial protein synthesis. Tobramycin may also destabilize bacterial memebrane by binding to 16 S 16 S r-RNA. An active transport mechanism for aminoglycoside uptake is necessary in the bacteria in order to attain a significant intracellular concentration of tobramycin.
- toxicity: LD<sub>50</sub>=441mg/kg (s.c. in mice)
- absorprion: The bioavailability of tobramycin may vary because of individual differences in nebulizer performance and airway pathology.
- halflife: The elimination half-life of tobramycin from serum is approximately 2 hours after intravenous (IV) administration.
- roouteelimination:
- volumedistribution:
- clearance: